<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04476108</url>
  </required_header>
  <id_info>
    <org_study_id>17535</org_study_id>
    <secondary_id>H0P-MC-NP01</secondary_id>
    <nct_id>NCT04476108</nct_id>
  </id_info>
  <brief_title>Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain</brief_title>
  <official_title>Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to test the safety and efficacy of the study drug LY3016859 for the&#xD;
      treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain&#xD;
      master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new&#xD;
      treatments for chronic pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">January 9, 2023</completion_date>
  <primary_completion_date type="Actual">July 8, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline in Average Pain Intensity as Measured by the NRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Total Interference Score</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline in the BPI-SF Total Interference Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline for Overall Improvement as Measured by Patient's Global Impression of Change</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline for Overall Improvement as Measured by Patient's Global Impression of Change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline for Worst Pain Intensity as Measured by NRS</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline for Worst Pain Intensity as Measured by NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Visual Analog Scale (VAS) for Pain</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline on the VAS for Pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Sleep Scale from the Medical Outcomes Study (MOS Sleep Scale)</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline on the Sleep Scale from the MOS Sleep Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Rescue Medication</measure>
    <time_frame>Baseline up to Week 8</time_frame>
    <description>Total Amount of Rescue Medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the EuroQol-5D 5 Level Questionnaire (EQ-5D-5L)</measure>
    <time_frame>Baseline, up to Week 8</time_frame>
    <description>Change from Baseline on the EQ-5D-5L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Diabetic Peripheral Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>LY3016859</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3016859 administered intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3016859</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3016859</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a visual analog scale (VAS) pain value ≥40 and &lt;95 during screening.&#xD;
&#xD;
          -  Have a history of daily pain for at least 12 weeks based on participant report or&#xD;
             medical history.&#xD;
&#xD;
          -  Have a value of ≤30 on the pain catastrophizing scale.&#xD;
&#xD;
          -  Have a body mass index &lt;40 kilograms per meter squared (kg/m²) (inclusive).&#xD;
&#xD;
          -  Are willing to maintain a consistent regimen of any ongoing nonpharmacologic&#xD;
             pain-relieving therapies (for example, physical therapy) and will not start any new&#xD;
             nonpharmacologic pain-relieving therapies during study participation.&#xD;
&#xD;
          -  Are willing to discontinue all medications taken for chronic pain conditions for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Have daily symmetrical foot pain secondary to peripheral neuropathy present for at&#xD;
             least 6 months and as diagnosed through use of the Michigan Neuropathy Screening&#xD;
             Instrument Part B ≥3 (©University of Michigan).&#xD;
&#xD;
          -  Have a history and current diagnosis of type 1 or type 2 diabetes mellitus.&#xD;
&#xD;
          -  Have stable glycemic control as indicated by a glycated hemoglobin ≤11 at time of&#xD;
             screening.&#xD;
&#xD;
          -  Are men, or women able to abide by reproductive and contraceptive requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have second- or third-degree atrioventricular (AV) heart block or AV dissociation or&#xD;
             history of ventricular tachycardia.&#xD;
&#xD;
          -  Have had a procedure within the past 6 months intended to produce permanent sensory&#xD;
             loss in the target area of interest (for example, ablation techniques).&#xD;
&#xD;
          -  Have surgery planned during the study for any reason, related or not to the disease&#xD;
             state under evaluation.&#xD;
&#xD;
          -  Have, in the judgment of the investigator, an acute, serious, or unstable medical&#xD;
             condition or a history or presence of any other medical illness that would preclude&#xD;
             study participation.&#xD;
&#xD;
          -  There is an inability to rule out other causative or confounding sources of pain in&#xD;
             the primary condition under study.&#xD;
&#xD;
          -  Have had cancer within 2 years of baseline, except for cutaneous basal cell or&#xD;
             squamous cell carcinoma resolved by excision.&#xD;
&#xD;
          -  Have a substance use disorder as defined by the Diagnostic and Statistical Manual of&#xD;
             Mental Disorders (5th edition; DSM-5; American Psychiatric Association).&#xD;
&#xD;
          -  Have congenital QT prolongation or QT interval corrected for heart rate using&#xD;
             Fridericia's formula (QTcF) interval measurement &gt;450 milliseconds (msec) for male&#xD;
             participants, &gt;470 msec for female participants, or &gt;480 msec for participants with&#xD;
             bundle branch block.&#xD;
&#xD;
          -  Have any clinically important abnormality at screening, as determined by investigator,&#xD;
             in physical or neurological examination, vital signs, electrocardiogram (ECG), or&#xD;
             clinical laboratory test results that could be detrimental to the participant or could&#xD;
             compromise the study.&#xD;
&#xD;
          -  Have a positive human immunodeficiency virus (HIV) test result at screening.&#xD;
&#xD;
          -  Are, in the judgment of the investigator, actively suicidal and therefore deemed to be&#xD;
             at significant risk for suicide.&#xD;
&#xD;
          -  Have an intolerance to acetaminophen or paracetamol or any of its excipients.&#xD;
&#xD;
          -  Have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2&#xD;
             years prior to screening.&#xD;
&#xD;
          -  Have a current drug-induced neuropathy, for example, due to some types of&#xD;
             chemotherapy, or other types of peripheral neuropathy.&#xD;
&#xD;
          -  Have known hereditary motor, sensory or autonomic neuropathies.&#xD;
&#xD;
          -  Have an estimated glomerular filtration rate (eGFR) of less than 70&#xD;
             milliliters/minute/1.73m² during screening.&#xD;
&#xD;
          -  Have any clinically serious or unstable cardiovascular, musculoskeletal disorder,&#xD;
             gastrointestinal, endocrinologic, hematologic, hepatic, metabolic, urologic,&#xD;
             pulmonary, dermatologic, immunologic, or ophthalmologic disease within 3 months of&#xD;
             baseline.&#xD;
&#xD;
          -  Have megaloblastic anemia or combined degeneration of the spinal cord.&#xD;
&#xD;
          -  Have received any antibodies against nerve growth factor (NGF), or antibodies against&#xD;
             EGFR, or EGFR tyrosine kinase inhibitors.&#xD;
&#xD;
          -  Have a history of allergic reactions to monoclonal antibodies, or clinically&#xD;
             significant multiple or severe drug allergies, including but not limited to erythema&#xD;
             multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or&#xD;
             exfoliative dermatitis.&#xD;
&#xD;
          -  Have a history or presence of uncontrolled asthma, eczema, significant atopy,&#xD;
             significant hereditary angio-edema or common variable immune deficiency.&#xD;
&#xD;
          -  Have fibromyalgia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM -5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simon Williamson Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - US</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research - Glendale</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irvine Clinical Research Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VIN-Julie Schwartzbard</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - US</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - US</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin E. Hale M.D., P.A.</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc - Orlando</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Infusion Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices and Research</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedVadis Research Corporation</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Research Group, Inc.</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - US</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center For Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading,LLC</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - US</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - US</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus - US</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007-4209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latin Clinical Trial Center</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/56qE3cITLpaXlG6KcqLoKQ</url>
    <description>A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

